Literature DB >> 16202728

The impact of obesity and age on quality of life in gynecologic surgery.

Vivian E von Gruenigen1, Karen M Gil, Heidi E Frasure, Eric L Jenison, Michael P Hopkins.   

Abstract

OBJECTIVE: This study was undertaken to prospectively evaluate the effect of early stage endometrial cancer, age, and obesity on quality of life (QOL). STUDY
DESIGN: Women undergoing surgery for endometrial cancer or an adnexal mass determined at surgery to be benign (controls) were enrolled preoperatively and followed for 6 months.
RESULTS: Seventy-nine women completed the study. Functional Assessment of Cancer Therapy (FACT-G) scores increased significantly in all women; however, significant differences by patient weight and age were obtained. Obesity was associated with decreased physical FACT-G and SF-36 scores. Older women had lower SF-36 physical scores, higher emotional scores, and less change over time.
CONCLUSION: Women with early endometrial cancer had similar changes in QOL as those who received surgery for benign disease. Obese and elderly women had domain alterations. Given the aging population and rising incidence of obesity, these results emphasize the need for QOL interventions in postoperative gynecologic care of these patients.

Entities:  

Mesh:

Year:  2005        PMID: 16202728     DOI: 10.1016/j.ajog.2005.03.038

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  25 in total

1.  Response to an exercise intervention after endometrial cancer: differences between obese and non-obese survivors.

Authors:  K Basen-Engquist; C Carmack; J Brown; A Jhingran; G Baum; J Song; S Scruggs; M C Swartz; M G Cox; K H Lu
Journal:  Gynecol Oncol       Date:  2014-04       Impact factor: 5.482

2.  Physical activity-related differences in body mass index and patient-reported quality of life in socioculturally diverse endometrial cancer survivors.

Authors:  Amerigo Rossi; Carol Ewing Garber; Gurpreet Kaur; Xiaonan Xue; Gary L Goldberg; Nicole S Nevadunsky
Journal:  Support Care Cancer       Date:  2017-02-16       Impact factor: 3.603

3.  Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes.

Authors:  Kemi M Doll; Alison K Kalinowski; Anna C Snavely; Debra E Irwin; Jeannette T Bensen; Victoria L Bae-Jump; Kenneth H Kim; Linda Van Le; Daniel L Clarke-Pearson; Paola A Gehrig
Journal:  Cancer       Date:  2014-09-23       Impact factor: 6.860

4.  The effect of body mass index on surgical outcomes and survival following pelvic exenteration.

Authors:  David A Iglesias; Shannon N Westin; Vijayashri Rallapalli; Marilyn Huang; Bryan Fellman; Diana Urbauer; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

5.  Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.

Authors:  Lucas Minig; Jorge Iván Vélez; Edward L Trimble; Roberto Biffi; Angelo Maggioni; Diana D Jeffery
Journal:  Support Care Cancer       Date:  2012-08-29       Impact factor: 3.603

6.  Cancer-related impairments influence physical activity in uterine cancer survivors.

Authors:  Sean M Hammer; Justin C Brown; Saya Segal; Christina S Chu; Kathryn H Schmitz
Journal:  Med Sci Sports Exerc       Date:  2014-12       Impact factor: 5.411

7.  Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression.

Authors:  Wei Zhang; Jo-Hsin Chen; Irene Aguilera-Barrantes; Chung-Wai Shiau; Xiugui Sheng; Li-Shu Wang; Gary D Stoner; Yi-Wen Huang
Journal:  Mol Nutr Food Res       Date:  2016-07-25       Impact factor: 5.914

8.  Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.

Authors:  Weiya Z Wysham; Dario R Roque; Jianjun Han; Lu Zhang; Hui Guo; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

9.  Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Authors:  Leigh A Cantrell; Chunxiao Zhou; Alberto Mendivil; Kimberly M Malloy; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-10-12       Impact factor: 5.482

Review 10.  PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.

Authors:  Felicia Roncolato; Kristina Lindemann; Melina L Willson; Julie Martyn; Linda Mileshkin
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.